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Therapeutic effect of all-trans retinoic acid on rats with anti-GBM
antibody glomerulonephritis.
Background. All-trans retinoic acid (ATRA) has antiprolif-
erative and anti-inflammatory effects and is currently used in
the treatment of leukemia and dermatologic diseases. We tested
the therapeutic potential of ATRA on anti-glomerular base-
ment membrane (GBM) glomerulonephritis rats.
Methods. Glomerulonephritis was induced in male Wistar-
Kyoto rats on day 0 by an intravenous injection of antirat
GBM antibody. On day 14 after the induction of anti-GBM
glomerulonephritis, some rats were sacrificed (N 5). Another
10 rats were divided into two groups: the vehicle group (N  5)
and the ATRA treated group (N  5). ATRA was orally
administrated from day 14 to day 27 after disease induction.
Blood pressure, body weight, urinary protein excretion, and blood
chemistry was determined on days 1, 14, 21, and 27. Kidney
samples were obtained on day 28. The kidneys were examined
with periodic acid-Schiff staining (PAS) and immunohisto-
chemistry using antibodies against the proliferative cell nuclear
antigen (PCNA), rat monocyte and macrophage (ED-1), and
-smooth muscle actin (-SMA). Glomerular RNA was ex-
tracted from isolated glomeruli, and reverse transcription (RT)
followed by polymerase chain reaction (PCR) was performed.
Results. ATRA administration produced a 55% reduction
of proteinuria in glomerulonephritis rats. Light microscopic
analysis revealed severe necrosis/crescent formation (50% of
the glomerulus) affecting 34% of glomeruli in vehicle rats,
whereas ATRA treatment reduced the glomeruli showing se-
vere change to 14%. ATRA also significantly reduced PCNA-
positive cells, ED-1–positive cells and -SMA–positive area in
the glomeruli. RT-PCR analyses revealed that a wide variety of
genes including inflammation related [tumor necrosis factor-
(TNF-), interleukin-1 (IL-1), and CCAAT enhancer-bind-
ing protein  (C/EBP)], cell proliferation–related [platelet-
derived growth factor (PDGF)] and fibrosis-related [trans-
forming growth factor-1 (TGF-1), type I collagen, and-SMA)
genes were suppressed in the glomeruli of ATRA-treated rats.
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c-fos, c-jun, C/EBP.
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Conclusion. ATRA administration significantly reduced se-
vere necrosis/crescent formation and urinary protein excretion
in glomerulonephritis rats. Suppression of a wide variety of
gene expression may partly explain the mechanism of ATRA’s
antiproliferative and anti-inflammatory effects. These data sug-
gest a novel therapeutic application of ATRA toward glomeru-
lonephritis.
Crescentic glomerulonephritis is a disease that rapidly
progresses to renal failure in humans. In Wistar-Kyoto
rats, administration of a small dose of anti-glomerular base-
ment membrane (anti-GBM) antibody induces severe nec-
rotizing glomerulonephritis with crescent formation [1].
Retinoic acids, which are biologically active deriva-
tives of vitamin A, are necessary for normal growth, main-
tenance of tissues, reproduction, immune response, and
survival [2]. Retinoic acid receptors belong to the super-
gene family of ligand-inducible transcriptional regula-
tory factors that includes steroid hormone, thyroid hor-
mone, and vitamin D3 receptors as well as the peroxisome
proliferator–activated receptors (PPAR) and others [3].
Retinoid receptors are nuclear receptors, which enter
the cell nucleus only after a ligand has been bound. They
bind to specific sequence elements on the promoters of
responsive genes, which allow the retinoid receptors to
directly modulate gene transcription [4].
Retinoic acids are not complete newcomers in the area
of human therapy. In dermatology, retinoids have been
used for the treatment of acne, psoriasis, and neoplastic
processes [5].
Recently, in anti-Thy1.1 nephritis, treatment of ne-
phritic rats with all-trans retinoic acid (ATRA) or iso-
tretinoin (13-cis RA) effectively limited renal damage
and mesangial cell proliferation [6]. The retinoic acids
attenuated the increase in glomerular cell proliferation,
glomerular transforming growth factor-1 (TGF-1) ex-
pression, and urinary albumin excretion. These results
indicate that the properties of retinoic acids to down-
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regulate inflammatory and proliferative responses makes
them attractive potential candidates for therapeutic use
in renal disease.
In the present study, we tested the therapeutic efficacy
of ATRA on anti-GBM antibody–induced renal injury.
We started the ATRA therapy at 14 days after disease
induction, when the disease is fully developed.
We found that urinary protein excretion was reduced
in ATRA-treated group along with a significant attenua-
tion of glomerular injury. A wide variety of glomerular
gene expression was suppressed in ATRA-treated group,
which may partly contribute to the therapeutic efficacy
of ATRA on renal disease.
METHODS
Experimental protocol
Male Wistar-Kyoto rats, aged 12 weeks, were used in
the present study. Glomerulonephritis was induced in 15
rats on day 0 by a single intravenous injection of 25 L/
100 g body weight of anti-rat GBM antiserum as pre-
viously reported [7]. Five rats were sacrificed on day 14.
We divided the remaining 10 rats into two groups: the
vehicle group, the anti-GBM glomerulonephritis without
treatment (N  5), and the ATRA-treated group (N 
5), the anti-GBM glomerulonephritis group treated by
ATRA. ATRA was mixed with sesame oil (9 mg/mL)
and was orally administrated at a dose of 30 mg/kg body
weight using gavage tube once daily from day 14 to day
27. Blood pressure and body weight was determined on
days 1, 14, 21, and 27. Blood pressure was measured by
blood pressure monitor for rats and mice model MK-
1100 (Muromachi Kikai Co., Ltd., Tokyo, Japan).
Proteinuria and creatinine determination
For determination of urinary protein excretion, rats
were placed in metabolic cages and urine was collected
for 24 hours on days 1, 14, 21, and 27. Blood samples
were taken from tail vein on the same time points. Uri-
nary protein concentration was determined by pyrogallol
red-molybdate complex method using a Micro TP-test
WAKO (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) [8]. Serum and urinary creatinine concentration
was determined by Jaffe method using a Creatinine-test
WAKO (Wako Pure Chemical Industries, Ltd.).
RNA isolation from glomeruli
Both vehicle-treated rats and ATRA-treated rats were
sacrificed on day 28. Both kidneys were removed and
partially preserved for histologic analysis. Glomeruli
were isolated by differential sieving as described pre-
viously [9]. Glomerular total RNA was extracted from
isolated glomeruli by the acid guanidinium thiocyanate-
phenol-chloroform method [10].
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Semiquantitative reverse transcription-polymerase
chain reaction
Reverse transcription (RT) was performed as follows:
4 L first-strand RT buffer was added to 0.4 g of total
RNA from isolated glomeruli [final concentration of 50
mmol/L Tris (hydroxymethyl) aminomethane hydro-
chloride, pH 8.3, 75 mmol/L KCl, and 3 mmol/L MgCl2],
2.5 L H2O, 0.5 L RNase inhibitor (55 U), 1 L of 10
mmol/L deoxynucleotide mixture, 1 L random primer
[0.02 A260 absorbance units of hexadeoxyribonucleotide
mixture (p(dN)6) per reaction], 2 L of 0.1 mol/L dithi-
othreitol, and 1 L Moloney murine leukemia virus re-
verse transcriptase (MMLV transcriptase) (Gibco BRL,
Gaithersburg, MD, USA). Reaction tubes were incu-
bated at 30C for 10 minutes and 42C for 40 minutes.
At the end of the incubation, the reaction was stopped
by heating at 95C for 5 minutes to inactivate MMLV.
Polymerase chain reaction (PCR) was performed as
follows: 0.4 L of 10 mol/L forward and reverse primer
was added to 1 L of the RT reaction mixture, 2 L of
10 	 buffer (final concentration of 10 mmol/L Tris HCl,
pH 8.3, 50 mmol/L KCl, 1.5 mmol/L MgCl2, and 0.001%
gelatin), 14.5 L H2O, 1.6 L of 2.5 mmol/L deoxy-
nucleoside triphosphate (dNTP) mix, and 0.1 L of Taq
polymerase.
The primers that we used are listed in Table 1. The
primers for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), interleukin-1 (IL-1), tumor necrosis fac-
tor- (TNF-), TGF-1, and monocyte chemoattractant
protein-1 (MCP-1) were used as described previously
[11]. The primers for type I collagen (collagen I) were
used as previously reported [12]. The primers for inter-
cellular adhesion molecule-1 (ICAM-1) were used as pre-
viously reported [13]. The primers for rat c-fos, c-jun and
-smooth muscle actin (-SMA) were constructed based
on rat c-fos, c-jun and -SMA nucleotide sequences. The
primers for platelet-derived growth factor (PDGF) and
CCAAT enhancer-binding protein  (C/EBP) were de-
signed based on mouse PDGF and C/EBP nucleotide
sequences.
All PCR was performed using a thermal cycler, PCR
System 9700 (Perkin Elmer, Wellesley, MA, USA), using
the following parameters. After initial denaturation for
5 minutes at 95C, 25 to 32 cycles of sequential steps
denaturation was performed at 95C for 1 minute, an-
nealing at 55 to 64C for 1 minute, extension at 72C for
2 minutes, followed by a final incubation at 72C for 7
minutes. The primers and PCR conditions for each
primer set are summarized in Table 1.
The PCR products were separated by electrophoresis
on 2.0% agarose gels and visualized by ethidium bromide
staining. Each experiment included the amplification of
GAPDH, and the intensities of cDNA bands were quan-
tified with the computing densitometry Image Quant
(Molecular Dynamics, Sunnyvale, CA, USA), and were
normalized to those of the GAPDH band as reported
previously [12].
Histologic examination
The kidneys were perfused with cold autoclaved phos-
phate-buffered saline (PBS) and were removed. Tissues
for microscopic examination were fixed with 4% para-
formaldehyde overnight and then dehydrated by graded
ethanol, then paraffin embedded. Thin section was exam-
ined with periodic acid-Schiff (PAS) staining as de-
scribed previously [14]. Fifty glomeruli per section were
randomly selected and were assessed. Glomerular ap-
pearance was graded as normal, mild to moderate, or
severe injury (50% of glomerulus affected by necrosis/
crescent formation), and results were expressed as per-
centage of glomeruli examined. At the same time, glo-
merular area and necrosis/crescent formation area were
quantitatively measured under high-power magnification
(	400) by using computer-aided manipulator program
(Macscope; Mitani Corporation, Fukui, Japan), and the
percentage of the glomerular necrosis/crescent forma-
tion area was calculated.
Immunohistochemistry
PBS-perfused slices (4 m) of renal tissue obtained
from comparable renal areas in all rats were fixed in
methacarn solution (methanol 60%, chloroform 30%,
and acetic acid 10%) and processed using the direct or
indirect immunoperoxidase technique. The endogenous
peroxidase activity in tissue sections was blocked by incu-
bating in PBS with 3% hydrogen peroxide for 30 minutes.
Tissue sections were preincubated with goat or horse
serums diluted 1:20 with PBS for 30 minutes to block
the nonspecific staining and were then incubated with the
primary antibodies for 60 minutes at room temperature.
Glomerular cell proliferation was assessed by staining
with 19A2 (Coulter Corp., Hialeah, FL, USA), a mouse
monoclonal immunoglobulin M (IgM) antibody to the
proliferative cell nuclear antigen (PCNA). To assess the
invasion of macrophages, mouse IgG antirat monocyte
and macrophage (ED-1) antibody was used (Serotec,
Inc., Raleigh, NC, USA). To stain -SMA, mouse IgG
anti-SMA monoclonal antibodies were used (Immuno-
tech S.A., Cedex, Marseilles, France). To stain C/EBP,
rabbit IgG anti-C/EBP monoclonal antibodies (M-17)
was used (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA). Sections were then processed using an avi-
din-biotinylated peroxidase complex method (Vecta-
stain ABC kit; Vector Laboratories, Inc., Burlingame,
CA, USA) with diaminobenzidine as the chromogen.
The sections were counterstained with methyl green.
Sections labeled with PCNA and ED-1 monoclonal anti-
bodies were scored by the number of PCNA-positive
cells and ED-1–positive cells within the glomerulus. Count-
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Fig. 1. Effect of all-trans retinoic acid (ATRA) administration on anti-glomerular basement membrane (anti-GBM) glomerulonephritis. Periodic
acid-Schiff (PAS) staining of kidney on day 14 in anti-GBM glomerulonephritis rats (A), on day 28 in vehicle-treated rats (B), and ATRA-treated
rats (C). The severity of glomerular injury was graded as normal, mild to moderate, or severe (50% of glomerulus affected by necrosis/crescent
formation) (D). Vehicle-treated rats showed 89% injured glomeruli, with severe segmental necrosis/crescent formation affecting 34% of glomeruli.
ATRA-treated rats showed 67% injured glomeruli, with severe change in 14%. Glomerular necrosis/crescent formation area was quantitatively
analyzed by computer-aided manipulator program (E). The area was 24.9 
 3.9% on day 14. The area on day 28 in vehicle rats was 33.1 
 5.7%
and 17.9 
 4.4% in ATRA-treated rats.

ing of the marker positive cells was performed under
high-power (	 400) microscopy. The number of PCNA-
positive cells and ED-1–positive cells per glomerulus was
determined by the observation of randomly selected 50
glomeruli for each animal. All scoring was performed on
blinded slides by one of the authors. Glomerular -SMA–
positive and C/EBP area was quantitatively analyzed by
using computer-aided manipulator program, Macscope
(Mitani Corporation), as described previously [15, 16].
Statistical analysis
The results were given as means
 standard deviation.
The differences between vehicle-treated and ATRA-
treated groups were tested using the Student t test. Statis-
tically significant differences between groups were de-
fined as P values less than 0.05.
RESULTS
ATRA reduced renal injury
We examined whether ATRA administration could
ameliorate the renal injury of anti-GBM glomerulone-
phritis rats. On day 14, light microscopy of kidney tissue
of anti-GBM glomerulonephritis rats showed diffuse
necrotizing glomerulonephritis affecting 81% of glomer-
uli, with severe segmental necrosis/crescent formation
(50% of the glomerulus) affecting 14% of glomeruli.
On day 28, vehicle-treated rats showed diffuse necrotiz-
ing glomerulonephritis affecting 89% of glomeruli, with
severe necrosis/crescent formation affecting 34% of glo-
meruli. ATRA-treated rats showed diffuse necrotizing
glomerulonephritis affecting 67% of glomeruli, with se-
vere change in 14% (Fig. 1D). Computer-aided quantita-
tive analysis revealed that glomerular necrosis/crescent
formation area was also reduced from 33.1 
 5.7% to
17.9 
 4.4% (P  0.01) (Fig. 1E). We examined whether
ATRA could decrease the glomerular cell proliferation
assessed by the PCNA expression. The number of PCNA-
positive cells per glomerulus in ATRA-treated rats was

Fig. 2. Effect of all-trans retinoic acid (ATRA) administration on glomerular cell proliferation. Representative immunohistochemical photomicrographs
of glomeruli stained for proliferating cell nuclear antigen (PCNA) on day 28 in vehicle-treated rats (A), and ATRA-treated rats (B). Cell proliferation
was quantified with the number of PCNA-positive cells per glomerulus (C). The number was 6.5 
 1.3 in anti glomerular basement membrane (anti-
GBM) glomerulonephritis on day 14. The number in vehicle-treated rats was 5.2 
 2.2 and 2.2 
 0.43 in ATRA-treated rats (P  0.05).
significantly reduced (2.2 
 0.43) compared to that in
vehicle-treated glomerulonephritis rats (5.2 
 2.2) (Fig.
2). We examined macrophage infiltration by the number
of ED-1–positive cells per glomerulus. The number of
ED-1–positive cells was significantly reduced in ATRA-
treated rats compared with vehicle-treated rats (5.2 

0.96 vs. 9.3 
 2.4, respectively) (Fig. 3). To examine
the degree of phenotypic change of glomerular cells to
myofibroblasts, we measured the -SMA–positive area
of glomeruli. The -SMA–positive area was significantly
reduced from 8.3 
 1.3% to 3.7 
 0.3% by ATRA
administration (Fig. 4). To examine protein levels of
C/EBP in glomerulus, we performed the immunostain-
ing of C/EBP and measured the C/EBP-positive area
of glomeruli. The C/EBP-positive area was significantly
reduced from 21.9 
 4.2% to 14.2 
 3.5% by ATRA
administration (Fig. 5) on day 28. Of note, there was
no immunostaining of C/EBP in normal rat glomeruli,
suggesting its involvement in the pathologic process in
glomeruli (Fig. 5).
Effects of ATRA on glomerular gene expression
Histologic examination demonstrated that ATRA ad-
ministration ameliorated glomerular injury in anti-GBM
glomerulonephritis. To explore the underlying mecha-
nisms of this therapeutic efficacy, we examined the effects
of ATRA administration on glomerular gene expression
of wide variety of genes, including inflammation-related,
cell proliferation–related, and fibrosis-related genes by
semiquantitative PCR. TNF- and IL-1 mRNAs were
significantly reduced in ATRA-treated rats (Fig. 6).
TGF-1, type I collagen, and -SMA mRNA was reduced
in ATRA-treated rats compared with vehicle-treated rats
(Fig. 7). PDGF, MCP-1, and ICAM-1 mRNA was also
significantly suppressed in ATRA-treated rats (Fig. 8).
Additionally, c-fos and c-jun mRNAs, which are compo-
nents of activated protein 1 (AP-1), were significantly
reduced in ATRA-treated rats (Fig. 9). C/EBP mRNA
was significantly reduced in ATRA-treated rats (Fig. 10),
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Fig. 3. Effect of all-trans retinoic acid (ATRA) administration on macrophage infiltration. Representative immunohistochemical photomicrographs
of glomeruli stained for ED-1 on day 28 in vehicle-treated rats (A), and ATRA-treated rats (B). Macrophage infiltration was quantified with the
number of ED-1–positive cells per glomerulus (C). The number was 10.4
 2.0 in anti-glomerular basement membrane (anti-GBM) glomerulonephri-
tis on day 14. The number in vehicle-treated rats was 9.3 
 2.4 and 5.2 
 0.96 in ATRA-treated rats (P  0.01).

which coincides with the changes in glomerular immuno-
staining of C/EBP as shown in Figure 5.
Body weight
There was no significant difference in body weight
between the vehicle-treated and ATRA-treated rats (day 1,
300 
 9.6 g vs. 301 
 9.0 g; day 14, 339 
 11.8 g vs. 334 

7.4 g; day 27, 350 
 14.6 g vs. 342 
 11.0 g).
Urinary protein excretion
The rate of urinary protein excretion was markedly
increased after injection of anti-rat GBM antibody both
in vehicle- and ATRA treated glomerulonephritis rats
before the commencement of ATRA treatment. In
ATRA-treated group, the rate of urinary protein excre-
tion was significantly reduced. On day 21, 7 days after
the commencement of ATRA therapy, the rate of pro-
teinuria was reduced to 46% of that of vehicle-treated
rats in ATRA-treated rats and the suppression was con-
tinued until day 27 (Fig. 11). Creatinine clearance or
serum creatinine levels were not different between vehi-
cle- and ATRA-treated groups (data not shown).
Blood pressure
There was no significant difference in blood pressure
between the vehicle-treated and ATRA-treated groups
just before the commencement of ATRA administration.
On day 21, 7 days after ATRA treatment was started,
blood pressure was not different, but on day 27, 14 days
after the beginning of ATRA administration, blood pres-
sure was significantly lower in ATRA-treated rats com-
pared to vehicle-treated rats (Fig. 12).
DISCUSSION
In the present study, intravenous injection of antirat
GBM antibody induced necrotizing glomerulonephritis
affecting 81% of glomeruli and severe segmental necro-
sis/crescent formation affecting 14% of glomeruli on day
14, and severe segmental necrosis/crescent formation in-
creased to 34% of glomeruli on day 28 in vehicle-treated

Fig. 4. Effect of all-trans retinoic acid (ATRA) administration on glomerular -smooth muscle action (-SMA) expression. Representative
immunohistochemical photomicrographs of glomeruli stained for -SMA on day 28 in vehicle-treated rats (A), and ATRA-treated rats (B). Five
animals were analyzed for each group and 50 randomly selected high-power fields were quantitated with a computer-aided image manipulator
and averaged to obtain the value for each animal(C). -SMA–positive area in anti-GBM glomerulonephritis on day 14 was 4.7 
 1.1%. The area
in vehicle-treated rats was 8.3 
 1.3% and 3.7 
 0.3% in ATRA-treated rats (P  0.01).
rats. In this anti-GBM glomerulonephritis rat model,
acute glomerular injuries show a peak around day 15
and then sclerotic/fibrotic glomerular lesions develop
thereafter [17]. The percentages of affected glomeruli in
the present study are similar to those in the previous
report [18]. Anti-GBM glomerulonephritis rats showed
about 100 mg/day of proteinuria on day 14, which is
comparable to the level of proteinuria induced by the
same anti-GBM antibody [19]. In our experiment, ATRA
administration significantly reduced renal injury and uri-
nary protein excretion. In immunohistochemical study,
ATRA reduced the number of PCNA or ED-1–positive
cells in glomeruli. We also found that ATRA suppressed
mRNA expression of proliferation and inflammatory-
related genes, which may partly contribute to ATRA’s
antiproliferative and anti-inflammatory effects on glo-
merular injury.
The substantial local macrophage proliferation within
Bowman’s space in crescentic lesion has already been
documented in anti-GBM glomerulonephritis rats by
double staining of ED-1 and PCNA [20]. We stained
PCNA and ED-1 on consecutive sections and found
considerable overlapping of ED-1–positive cells in
PCNA-positive cells, although we did not perform dou-
ble staining. We speculate that some population of
PCNA-positive cells in glomeruli was ED-1–positive
macrophages.
It is now well established that glomerular macrophage
infiltration is closely related to the progression of renal
injury [21]. We found that ATRA administration signifi-
cantly suppressed the glomerular macrophage infiltration.
Glomerular expression of ICAM-1 and MCP-1 was also
significantly suppressed in ATRA-treated rats. Up-regu-
lation of glomerular ICAM-1 and MCP-1 expression was
previously demonstrated in anti-GBM glomerulonephritis
rats [7, 22]. Administration of anti-ICAM-1 antibody [22]
or anti-MCP-1 antibody [7] significantly suppressed mac-
rophage infiltration and urinary protein excretion in this
model. These results suggest that enhanced expression
of ICAM-1 and MCP-1 play a crucial role in renal injury
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Fig. 5. Effect of all-trans retinoic acid (ATRA) administration on glomerular CCAAT enhancer-binding protein  (C/EBP) expression. Represen-
tative immunohistochemical photomicrographs of glomeruli stained for C/EBP on day 28 in normal rats (A), vehicle-treated rats (B), and ATRA-
treated rats (C). Five animals were analyzed for each group and 50 randomly selected high-power fields were quantitated with a computer-aided
image manipulator and averaged to obtain the value for each animal(D). C/EBP-positive area in anti-glomerular basement membrane (anti-GBM)
glomerulonephritis on day 14 was 30.4 
 3.9%. The area in vehicle-treated rats was 21.9 
 4.2% and 14.2 
 3.5% in ATRA-treated rats (P  0.01).
Fig. 6. Effects of all-trans retinoic acid (ATRA) administration on
proinflammatory glomerular gene expression in anti-glomerular base-
ment membrane (anti-GBM) glomerulonephritis rats. (A ) Ethidium
bromide–stained gels. Vehicle-treated rats and ATRA-treated rats. The
level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was not
of anti-GBM glomerulonephritis. The reduction of renal
macrophage infiltration and proteinuria in our experiment
may partly be due to the attenuation of ICAM-1 or MCP-1
mRNA expression. Proinflammatory cytokines such as
TNF-, IL-1, and nitric oxide are known to activate
macrophages. ATRA decreased the level of nitric oxide
and TNF- in macrophage cell line [23]. In our study,
glomerular TNF- and IL-1 mRNA expression was
reduced in ATRA-treated rats. This result suggests that
ATRA reduces such proinflammatory cytokines and at-
tenuates macrophage activity. The attenuation of macro-
phage infiltration and activation may be one of the un-
significantly different. Tumor necrosis factor- (TNF-) and interleu-
kin-1 (IL-1) mRNA expression was significantly reduced by ATRA
administration. The intensities of cDNA bands were quantified with
the computing densitometry and normalized by GAPDH. (B) TNF-
mRNA was decreased to 55% and (C) IL-1 mRNA was decreased to
44% in ATRA-treated rats compared with vehicle-treated rats.
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Fig. 7. Effects of all-trans retinoic acid (ATRA)
administration on fibrosis related glomerular
gene expression in anti-glomerular basement
membrane (anti-GBM) glomerulonephritis rats.
(A) Ethidium bromide–stained gels. ATRA ad-
ministration significantly reduced transforming
growth factor-1 (TGF-1) (49%) (B), type
I collagen (47%) (C), and -smooth muscle
actin (-SMA) (38%) (D) mRNA expres-
sion. GAPDH is glyceraldehyde-3-phosphate
dehydrogenase.
Fig. 8. Effect of all-trans retinoic acid (ATRA)
administration on proliferation-related and
macrophage infiltration–related glomerular
gene expression in anti-glomerular basement
membrane (anti-GBM) glomerulonephritis rats.
(A ) Ethidium bromide–stained gels. ATRA
administration significantly reduced platelet-
derived growth factor (PDGF) (63%) (B),
monocyte chemoattractant protein-1 (MCP-1)
(42%) (C), and intercellular adhesion mole-
cule-1 (ICAM-1) (56%) (D) mRNA expres-
sion. GADPH is glyceraldehyde-3-phosphate
dehydrogenase.
derlying mechanisms of the therapeutic effect of ATRA
on anti-GBM antibody glomerulonephritis.
ATRA was shown to down-regulate H2O2-induced [24]
and fetal bovine serum (FBS)-stimulated [25] expression
of c-fos and c-jun in cultured mesangial cells. In our
study, glomerular c-fos and c-jun mRNAs were reduced
in ATRA-treated rats in vivo. Previous study demon-
strated that down-regulation of c-fos and c-jun mRNA
levels suggests a mechanism for anti-AP-1 activity by
ATRA [25]. Thus, the blunted gene expression of c-fos
and c-jun mRNA in ATRA-treated rats is supposed to
result in the down-regulation of AP-1 activity in the
glomeruli. MCP-1 expression is reported to be partly
regulated by AP-1 activation [26, 27]. MCP-1 production
stimulated by IL-1 was suppressed via inhibition of
nuclear factor-kappa B (NF-B) and AP-1 activation
[28]. On the other hand, overexpression of AP-1 protein
induced ICAM-1 gene expression [29]. Taken together,
down-regulation of ICAM-1 and MCP-1 in ATRA-treated
rats may at least partly be explained by the suppressive
effects of ATRA on c-fos and c-jun mRNAs. There have
been some reports demonstrating that AP-1 regulates
TGF- gene expression in variety of cells, including mes-
angial cells and tubular cells [30–33]. TGF-1 mRNA
expression was decreased in ATRA-treated rats in our
study, which might be related to the suppression of AP-1
component genes. Morath et al [34] also suggested that
the beneficial effects of ATRA on anti-Thy1.1 nephritis
may be due to a suppression of renal TGF-1. TGF-
is supposed to play a central role in the progression
of tissue fibrosis via stimulation of extracellular matrix
components (ECM) synthesis and cellular phenotypic
change to myofibroblasts. -SMA is one of the typical
molecular markers of myofibroblasts and is known to be
induced by TGF- [35]. The reduction of TGF-1 mRNA
expression may result in the reduction of glomerular
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Fig. 9. Effect of all-trans retinoic acid (ATRA) administration on c-fos
and c-jun mRNA in anti-glomerular basement membrane (anti-GBM)
glomerulonephritis rats. (A ) Ethidium bromide-stained gels. The level
of c-fos (B) and c-jun (C) mRNA expression was significantly reduced
by ATRA administration (69% and 49%, respectively). GAPDH
is glyceraldehyde-3-phosphate dehydrogenase.
Fig. 10. Effect of all-trans retinoic acid (ATRA) administration on
CCAAT enhancer-binding protein (C/EBP) mRNA in anti-glomeru-
lar basement membrane (anti-GBM) glomerulonephritis rats. (A )
Ethidium bromide–stained gels. The level of C/EBP mRNA (B ) ex-
pression was significantly reduced by ATRA administration (56%).
GAPDH is glyceraldehyde-3-phosphate dehydrogenase.
myofibroblast expansion revealed by -SMA expression
and reduction of type I collagen mRNA expression.
Myofibroblasts are recognized as the key to under-
stand the reconstruction and excessive matrix formation
in injured tissue. We have been investigating the pheno-
typic change from renal cells to myofibroblasts in the
process of progressive renal diseases in animal models
and human glomerulonephritis [15, 35, 36]. -SMA is
a typical molecular marker of myofibroblasts, and we
hypothesized that the molecular mechanisms underlying
the induction of -SMA in myofibroblasts are closely
Fig. 11. Effect of all-trans retinoic acid (ATRA) administration on
urinary protein excretion in anti-glomerular basement membrane (anti-
GBM) glomerulonephritis rats. Urinary protein excretion was de-
creased to 46% of untreated levels 7 days after ATRA administration.
*P  0.05 vehicle vs. ATRA treated rats.
Fig. 12. Effect of all-trans retinoic acid (ATRA) administration on
blood pressure in anti-glomerular basement membrane (anti-GBM)
glomerulonephritis rats. There was no difference between two groups
7 days after ATRA administration, but blood pressure was significantly
lower in ATRA-treated group 14 days after the beginning of ATRA
administration. *P  0.05 vehicle vs. ATRA-treated rats.
related to the molecular pathophysiology of progressive
renal disease leading to renal fibrosis. We speculated
any factor that promotes -SMA expression might play
an important role for transdifferentiation to myofi-
broblast and progression of tissue injury. Then, we iden-
tified C/EBP as a major transcription factor that induces
phenotypic change in renal disease. We also found that
C/EBP-deficient mice show a significant reduction in
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-SMA expression along with substantial amelioration
in renal damage in Habu venom glomerulonephritis or
unilateral ureteral obstruction. In the present study, we
demonstrated a significant reduction of both C/EBP
and -SMA mRNA or protein expression in glomeruli
from ATRA-treated anti-GBM glomerulonephritis rats.
This observation and our results of other study using C/
EBP-deficient mice further support the role of C/EBP
in myofibroblast formation [(manuscript in preparation)
abstract; Takeji M, et al, J Am Soc Nephrol 13:295A, 2002].
We speculate that the suppression of C/EBP mRNA is
at least part of the molecular mechanism of therapeutic
effect of ATRA in anti-GBM glomerulonephritis.
It was already demonstrated that ATRA lowered the
high blood pressure in anti-Thy1.1 glomerulonephritis
rats [6]. In our experiment, blood pressure of ATRA-
treated rats was significantly lower compared with vehi-
cle-treated rats 14 days after ATRA administration, al-
though no significant difference was observed after 7
days of treatment. Interestingly, it was recently shown
that ATRA might have an inhibitory effect on renin-
angiotensin system (RAS) in the kidney [37]. Thus, the
lower blood pressure at 14 days after ATRA administra-
tion may be related to the suppression of RAS compo-
nent genes, and alternatively, be secondary to the ame-
lioration of renal injury by ATRA treatment.
CONCLUSION
We have demonstrated therapeutic effects of ATRA
on anti-GBM antibody glomerulonephritis rats revealed
by histologic changes, urinary protein excretion, and
blood pressure. A wide variety of disease-related gene
expression in glomeruli was blunted in ATRA-treated
rats, which may explain the molecular mechanisms of
therapeutic effects of ATRA in glomerulonephritis rats.
Clinical feasibility of ATRA treatment in progressive
renal diseases is expected to be established with further
investigation.
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